Collin Blakely | UCSF Profiles

Collin Blakely, MD, PhD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
ORCID ORCID Icon0000-0001-8134-3651 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of WashingtonB.S.1997Molecular and Cellular Biology
    University of PennsylvaniaPh.D.2006Cell and Molecular Biology
    University of PennsylvaniaM.D.2007Medicine
    University of Pennsylvania Health SystemResidency2009Internal Medicine
    UCSFFellowship2011Medical Oncology
    Collapse Awards and Honors
    Damon Runyon Cancer Research Foundation2018  - 2021Damon Runyon Clinical Investigator Award
    Doris Duke Charitable Foundation2018  - 2012Clinical Scientist Award
    V Foundation2018  - 2020V Scholar Award
    AACR2014  - 2016AACR BioOncology Fellowship
    Uniting Against Lung Cancer2014  - 2016Legacy Award
    Bonnie J. Addario Lung Cancer Foundation2013Research Grant

    Collapse Overview 
    Collapse Overview
    Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-, and ALK-targeted therapies, and identifying new targets for molecular-directed therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Targeting MEK in non-small cell lung cancer. Curr Probl Cancer. 2024 Feb 09; 101065. Lara MS, Blakely CM, Riess JW. PMID: 38341356.
      View in: PubMed   Mentions:    Fields:    
    2. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nat Genet. 2024 Jan; 56(1):60-73. Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, Boumelha J, Kerr DL, Blakely CM, Manabe T, Martinez-Ruiz C, Bakker B, De Dios Palomino Villcas J, I Vokes N, Dietzen M, Angelova M, Gini B, Tamaki W, Allegakoen P, Wu W, Humpton TJ, Hill W, Tomaschko M, Lu WT, Haderk F, Al Bakir M, Nagano A, Gimeno-Valiente F, de Carné Trécesson S, Vendramin R, Barbè V, Mugabo M, Weeden CE, Rowan A, McCoach CE, Almeida B, Green M, Gomez C, Nanjo S, Barbosa D, Moore C, Przewrocka J, Black JRM, Grönroos E, Suarez-Bonnet A, Priestnall SL, Zverev C, Lighterness S, Cormack J, Olivas V, Cech L, Andrews T, Rule B, Jiao Y, Zhang X, Ashford P, Durfee C, Venkatesan S, Temiz NA, Tan L, Larson LK, Argyris PP, Brown WL, Yu EA, Rotow JK, Guha U, Roper N, Yu J, Vogel RI, Thomas NJ, Marra A, Selenica P, Yu H, Bakhoum SF, Chew SK, Reis-Filho JS, Jamal-Hanjani M, Vousden KH, McGranahan N, Van Allen EM, Kanu N, Harris RS, Downward J, Bivona TG, Swanton C. PMID: 38049664; PMCID: PMC10786726.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    3. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. PMID: 37068173.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    4. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. J Natl Compr Canc Netw. 2023 06; 21(6):609-616.e4. Douglas MP, Ragavan MV, Chen C, Kumar A, Gray SW, Blakely CM, Phillips KA. PMID: 37308126; PMCID: PMC10846388.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol. 2023 07; 18(7):907-921. He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, Olson P, Latven L, Yan X, Shazer R, Leal TA. PMID: 36842467; PMCID: PMC10330304.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    6. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. J Thorac Oncol. 2023 05; 18(5):650-656. Kim DW, Kim SW, Camidge DR, Shu CA, Marrone KA, Le X, Blakely CM, Park K, Chang GC, Patel SP, Kar G, Cooper ZA, Samadani R, Pluta M, Kumar R, Ramalingam S. PMID: 36641093.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    7. Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clin Res Rep. 2023 Mar; 4(3):100459. Ji J, Aredo JV, Piper-Vallillo A, Huppert L, Rotow JK, Husain H, Stewart S, Cobb R, Wakelee HA, Blakely CM, Wong ML, Gubens MA, Madani MH, Digumarthy SR, McCoach C, Piotrowska Z, Neal JW, Riess JW. PMID: 36879929; PMCID: PMC9984841.
      View in: PubMed   Mentions: 7  
    8. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. Lung Cancer. 2023 03; 177:59-72. Blakely CM, Weder W, Bubendorf L, He J, Majem M, Shyr Y, Chaft JE. PMID: 36736076.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC. JTO Clin Res Rep. 2022 Dec; 3(12):100436. Lara MS, Gubens MA, Bacaltos B, Daran L, Lim SL, Li T, Gandara DR, Bivona TG, Riess JW, Blakely CM. PMID: 36545322; PMCID: PMC9761844.
      View in: PubMed   Mentions: 2  
    10. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. Cancer Discov. 2022 Nov 02; 12(11):2666-2683. Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. PMID: 35895872; PMCID: PMC9627128.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    11. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 2022 07 01; 132(13). Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. PMID: 35579943; PMCID: PMC9246391.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    12. Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Sci Transl Med. 2022 03 30; 14(638):eabc7480. Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, Bivona TG, Wood KC. PMID: 35353542; PMCID: PMC9516479.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    13. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 12; 19(12):1441-1464. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. PMID: 34902832; PMCID: PMC10203822.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    14. Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. J Vis Exp. 2021 11 22; (177). Barbosa Rabago D, Blakely CM, Haderk F, Bivona TG. PMID: 34866626.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. J Am Geriatr Soc. 2022 01; 70(1):136-149. Wong ML, Shi Y, Smith AK, Miaskowski C, Boscardin WJ, Cohen HJ, Lam V, Mazor M, Metzger L, Presley CJ, Williams GR, Loh KP, Ursem CJ, Friedlander TW, Blakely CM, Gubens MA, Allen G, Shumay D, Walter LC. PMID: 34611887; PMCID: PMC8742783.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021 11; 22(6):587-595. Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. PMID: 34544620.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021 Nov; 17(31):4045-4055. Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. PMID: 34278827; PMCID: PMC8530153.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    18. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clin Res Rep. 2021 Feb; 2(2):100114. Yang JC, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, Bazhenova L, Carcereny Costa E, Chiari R, Hsia TC, Golsorkhi T, Despain D, Shih D, Popat S, Wakelee H. PMID: 34589984; PMCID: PMC8474221.
      View in: PubMed   Mentions: 8  
    19. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2020 09 01; 3(9):e209750. Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS. PMID: 32997124; PMCID: PMC7527870.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    20. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 09 03; 182(5):1232-1251.e22. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. PMID: 32822576; PMCID: PMC7484178.
      View in: PubMed   Mentions: 221     Fields:    Translation:HumansCells
    21. Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies. Clin Cancer Res. 2020 07 15; 26(14):3499-3500. Blakely CM, McCoach CE. PMID: 32366673.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J Thorac Dis. 2020 May; 12(5):2883-2895. Gini B, Thomas N, Blakely CM. PMID: 32642201; PMCID: PMC7330397.
      View in: PubMed   Mentions: 9  
    23. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators. PMID: 31838007; PMCID: PMC7461630.
      View in: PubMed   Mentions: 473     Fields:    Translation:Humans
    24. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. Expert Rev Anticancer Ther. 2019 12; 19(12):1061-1075. Blakely CM, Riess JW. PMID: 31809604.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    25. A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations. Clin Cancer Res. 2019 12 15; 25(24):7269-7271. Blakely CM. PMID: 31611281.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. PMID: 31548343; PMCID: PMC6980768.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    27. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019 02 26; 21(3):21. Halliday PR, Blakely CM, Bivona TG. PMID: 30806814.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    28. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Res. 2019 02 01; 79(3):546-556. Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG. PMID: 30538120; PMCID: PMC6359944.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    29. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019 01; 25(1):111-118. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. PMID: 30478424; PMCID: PMC6324945.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansAnimalsCells
    30. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clin Lung Cancer. 2019 03; 20(2):e137-e141. Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. PMID: 30553716.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    31. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec; 13(12):1818-1831. Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. PMID: 30268698.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    32. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 09; 20(9):1064-1073. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. PMID: 30104724; PMCID: PMC6115280.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansAnimalsCells
    33. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 06 15; 24(12):2758-2770. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. PMID: 29599410; PMCID: PMC6157019.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    34. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. PMID: 29125731; PMCID: PMC5773933.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    35. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415; PMCID: PMC5709185.
      View in: PubMed   Mentions: 249     Fields:    Translation:HumansCells
    36. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 01; 19(1):58-64. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. PMID: 28645632.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    37. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 03 13; 7:44206. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. PMID: 28287179; PMCID: PMC5347024.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    38. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 01; 49(1):87-96. Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. PMID: 27869830; PMCID: PMC5195898.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansAnimalsCells
    39. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer. 2016 09; 17(5):466-469. McCoach CE, Bivona TG, Blakely CM, Doebele RC. PMID: 27378174; PMCID: PMC5378381.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    40. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. PMID: 26301689; PMCID: PMC4734742.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCells
    41. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. PMID: 25843712; PMCID: PMC4394036.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCells
    42. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012 Oct; 2(10):872-5. Blakely CM, Bivona TG. PMID: 23071030; PMCID: PMC3475614.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    43. Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011 Oct; 11(10):1607-18. Blakely C, Jahan T. PMID: 21999134.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    44. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res. 2006 Jun 15; 66(12):6421-31. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA. PMID: 16778221.
      View in: PubMed   Mentions: 48     Fields:    Translation:AnimalsCells
    45. Developmental stage determines the effects of MYC in the mammary epithelium. Development. 2005 Mar; 132(5):1147-60. Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, Chodosh LA. PMID: 15689376.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    46. The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation. J Biol Chem. 2002 Sep 27; 277(39):36109-17. Tan SL, Tareen SU, Melville MW, Blakely CM, Katze MG. PMID: 12138106.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    47. Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A. Virology. 2000 Dec 20; 278(2):501-13. Katze MG, Kwieciszewski B, Goodlett DR, Blakely CM, Neddermann P, Tan SL, Aebersold R. PMID: 11118372.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    48. Tissue specific expression of PKR protein kinase in aging B6D2F1 mice. Mech Ageing Dev. 2000 Mar 13; 114(2):123-32. Ladiges W, Morton J, Blakely C, Gale M. PMID: 10799709.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    49. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol. 1998 Sep; 18(9):5208-18. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. PMID: 9710605; PMCID: PMC109106.
      View in: PubMed   Mentions: 185     Fields:    Translation:AnimalsCells
    50. Regulation of interferon-induced protein kinase PKR: modulation of P58IPK inhibitory function by a novel protein, P52rIPK. Mol Cell Biol. 1998 Feb; 18(2):859-71. Gale M, Blakely CM, Hopkins DA, Melville MW, Wambach M, Romano PR, Katze MG. PMID: 9447982; PMCID: PMC108797.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Collin's Networks
    Concepts (289)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (73)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.